On October 23, 2023, a delegation from the Indonesian Ministry of Health visited Sinovac and visited the company's exhibition hall, vaccine workshop and R&D center.
The company's Chief Operating Officer Gao Qiang and Chairman of the Quality Management Committee Meng Weining accompanied and held discussions and exchanges.
The delegation from the Indonesian Ministry of Health includes Dr. Sunarto, Director of the Health Service Management Directorate of the General Administration of Health Management of the Indonesian Ministry of Health, Dr. Iwan Dakota, President and Director of the Indonesian National Cardiovascular Center and Harapan Kita Hospital, Dr. Dr. Iwan Dakota, President and Director of the Indonesian National Cancer Center and Dharmais Cancer Hospital. R. Soeko, Dr. Sudadi, deputy dean of the School of Medicine, Public Health and Nursing, Gajah Mada University, and others.
At the symposium, Gao Qiang reviewed the cooperation process between Sinovac and Indonesian partners after the outbreak of the COVID-19 epidemic, and with the support of the Chinese and Indonesian governments, from COVID-19 vaccine research to finished product supply and promotion of localized vaccine production. Gao Qiang introduction: Cooperation between China and Indonesia in the field of medical and health will be deeper. Sinovac has established a subsidiary in Indonesia and has so far promoted the approval of COVID-19 vaccine, hepatitis A vaccine and EV71 vaccine in Indonesia. In the future, Sinovac will take root in Indonesia for a long time, deepen exchanges with Indonesian parties in vaccines and other fields, carry out pragmatic cooperation, and continue to contribute to disease prevention and control in Indonesia and the joint construction of the 'Health Silk Road' between China and Indonesia and other ASEAN countries. share of strength.
Dr. Sunarto introduced in detail the national public health transformation project currently led by the Directorate General of Health Services Management of the Ministry of Health of Indonesia. He believes that the transformation of Indonesia's public health manpower system and public health technology is inseparable from the participation of high-tech enterprises like Sinovac. He hopes that Sinovac will give full play to its own advantages in the important transformation process of Indonesia's public health system and develop its expertise in medicine and In the field of high-end equipment, we will establish more in-depth cooperation with Indonesian parties.
Dr. R. Soeko said that he was deeply impressed by this visit to the Sinovac R&D and production base. He hopes that the younger generation in Indonesia can have the opportunity to come to China to study, so that they can learn professional knowledge and be equipped with strategies in the medical field. The ability to think. In addition, Dr. Sudadi also expressed the hope to increase cooperation between Chinese and Indonesian universities.
During the discussion, many experts mentioned their hope to strengthen exchanges and cooperation among experts from universities, research institutions, and medical institutions in the two countries in the future. Meng Weining said that Sinovac has always maintained an open attitude towards exchanges with all parties, and also hopes to build a bridge of cooperation through exchanges, bring more good products to Indonesia, and enhance the health and well-being of the Indonesian people.
About SINOVAC
Sinovac Biotech Ltd. (SINOVAC) is China's leading biotech enterprise. With the mission of 'providing vaccines to eliminate diseases for humans', it is committed to the research of human vaccines and related products. Development, production and sales to provide services for global disease prevention and control.
The vaccines developed by SINOVAC mainly include vaccines against viral hepatitis, influenza, pneumonia, polio, chickenpox, mumps and other common infectious diseases, as well as vaccines against SARS, H5N1 avian influenza, H1N1 pandemic influenza, EV71 hand, foot and mouth disease, novel Vaccines for emerging and emerging infectious diseases such as coronavirus infections.
The company's current 4 vaccines have passed World Health Organization pre-certification (inactivated hepatitis A vaccine, Sabin strain inactivated polio vaccine, live attenuated chickenpox vaccine) or are included in the emergency use list (new coronavirus inactivated vaccine). The quality of the vaccines is The management system has been recognized by international organizations and multinational drug regulatory authorities.
SINOVAC is constantly exploring opportunities in the international market and has exported vaccines to dozens of countries and international organizations.
Contact:
Tel: +86-10-8279-9800
Email: sinovac@sinovac.com
Email: lad@sinovac.com
Tel: +86-10-5689-7188
SINOVAC BIOTECH LTD. 
